nodes	percent_of_prediction	percent_of_DWPC	metapath
Trabectedin—Alkylating Activity—Mechlorethamine—lymphatic system cancer	0.504	0.591	CiPCiCtD
Trabectedin—Alkylating Activity—Carmustine—lymphatic system cancer	0.349	0.409	CiPCiCtD
Trabectedin—CYP2E1—Mitoxantrone—lymphatic system cancer	0.0217	0.248	CbGbCtD
Trabectedin—CYP2C19—Teniposide—lymphatic system cancer	0.0195	0.223	CbGbCtD
Trabectedin—CYP2C9—Teniposide—lymphatic system cancer	0.0162	0.185	CbGbCtD
Trabectedin—CYP3A4—Cytarabine—lymphatic system cancer	0.00956	0.109	CbGbCtD
Trabectedin—CYP3A4—Teniposide—lymphatic system cancer	0.00942	0.108	CbGbCtD
Trabectedin—CYP3A4—Mitoxantrone—lymphatic system cancer	0.00659	0.0753	CbGbCtD
Trabectedin—CYP3A4—Vincristine—lymphatic system cancer	0.00453	0.0518	CbGbCtD
Trabectedin—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.000209	0.00351	CcSEcCtD
Trabectedin—Thrombocytopenia—Teniposide—lymphatic system cancer	0.000208	0.00349	CcSEcCtD
Trabectedin—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.000207	0.00347	CcSEcCtD
Trabectedin—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.000206	0.00346	CcSEcCtD
Trabectedin—Leukopenia—Fludarabine—lymphatic system cancer	0.000205	0.00344	CcSEcCtD
Trabectedin—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.000204	0.00342	CcSEcCtD
Trabectedin—Anorexia—Teniposide—lymphatic system cancer	0.000203	0.0034	CcSEcCtD
Trabectedin—Hepatotoxicity—Methotrexate—lymphatic system cancer	0.000201	0.00337	CcSEcCtD
Trabectedin—Cough—Fludarabine—lymphatic system cancer	0.0002	0.00335	CcSEcCtD
Trabectedin—Pancytopenia—Carmustine—lymphatic system cancer	0.0002	0.00335	CcSEcCtD
Trabectedin—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.0002	0.00335	CcSEcCtD
Trabectedin—Hypotension—Teniposide—lymphatic system cancer	0.000199	0.00333	CcSEcCtD
Trabectedin—Necrosis—Methotrexate—lymphatic system cancer	0.000198	0.00332	CcSEcCtD
Trabectedin—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000197	0.00331	CcSEcCtD
Trabectedin—Neutropenia—Carmustine—lymphatic system cancer	0.000197	0.0033	CcSEcCtD
Trabectedin—Arthralgia—Fludarabine—lymphatic system cancer	0.000195	0.00327	CcSEcCtD
Trabectedin—Myalgia—Fludarabine—lymphatic system cancer	0.000195	0.00327	CcSEcCtD
Trabectedin—Haemoglobin—Bleomycin—lymphatic system cancer	0.000194	0.00325	CcSEcCtD
Trabectedin—Haemorrhage—Bleomycin—lymphatic system cancer	0.000193	0.00324	CcSEcCtD
Trabectedin—Pancytopenia—Vincristine—lymphatic system cancer	0.000191	0.0032	CcSEcCtD
Trabectedin—Dyspnoea—Teniposide—lymphatic system cancer	0.00019	0.00318	CcSEcCtD
Trabectedin—Neutropenia—Vincristine—lymphatic system cancer	0.000188	0.00315	CcSEcCtD
Trabectedin—Oedema—Fludarabine—lymphatic system cancer	0.000187	0.00314	CcSEcCtD
Trabectedin—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.000186	0.00312	CcSEcCtD
Trabectedin—Infection—Fludarabine—lymphatic system cancer	0.000186	0.00312	CcSEcCtD
Trabectedin—Decreased appetite—Teniposide—lymphatic system cancer	0.000185	0.0031	CcSEcCtD
Trabectedin—Vomiting—Mechlorethamine—lymphatic system cancer	0.000183	0.00308	CcSEcCtD
Trabectedin—Nervous system disorder—Fludarabine—lymphatic system cancer	0.000183	0.00308	CcSEcCtD
Trabectedin—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000183	0.00307	CcSEcCtD
Trabectedin—Neutropenia—Mitoxantrone—lymphatic system cancer	0.000183	0.00307	CcSEcCtD
Trabectedin—Stomatitis—Carmustine—lymphatic system cancer	0.000183	0.00307	CcSEcCtD
Trabectedin—Rash—Mechlorethamine—lymphatic system cancer	0.000182	0.00305	CcSEcCtD
Trabectedin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000182	0.00305	CcSEcCtD
Trabectedin—Weight decreased—Vincristine—lymphatic system cancer	0.000182	0.00305	CcSEcCtD
Trabectedin—Flushing—Bleomycin—lymphatic system cancer	0.000179	0.003	CcSEcCtD
Trabectedin—Anorexia—Fludarabine—lymphatic system cancer	0.000178	0.00299	CcSEcCtD
Trabectedin—Extravasation—Methotrexate—lymphatic system cancer	0.000178	0.00299	CcSEcCtD
Trabectedin—Weight decreased—Mitoxantrone—lymphatic system cancer	0.000177	0.00297	CcSEcCtD
Trabectedin—Stomatitis—Vincristine—lymphatic system cancer	0.000175	0.00293	CcSEcCtD
Trabectedin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000174	0.00292	CcSEcCtD
Trabectedin—Nausea—Mechlorethamine—lymphatic system cancer	0.000171	0.00288	CcSEcCtD
Trabectedin—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.000171	0.00287	CcSEcCtD
Trabectedin—Alopecia—Bleomycin—lymphatic system cancer	0.000171	0.00286	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00017	0.00286	CcSEcCtD
Trabectedin—Jaundice—Mitoxantrone—lymphatic system cancer	0.00017	0.00285	CcSEcCtD
Trabectedin—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00017	0.00285	CcSEcCtD
Trabectedin—Haemoglobin—Carmustine—lymphatic system cancer	0.000169	0.00284	CcSEcCtD
Trabectedin—Haemorrhage—Carmustine—lymphatic system cancer	0.000168	0.00283	CcSEcCtD
Trabectedin—Abdominal pain—Teniposide—lymphatic system cancer	0.000168	0.00282	CcSEcCtD
Trabectedin—Body temperature increased—Teniposide—lymphatic system cancer	0.000168	0.00282	CcSEcCtD
Trabectedin—Paraesthesia—Fludarabine—lymphatic system cancer	0.000168	0.00282	CcSEcCtD
Trabectedin—Dyspnoea—Fludarabine—lymphatic system cancer	0.000167	0.0028	CcSEcCtD
Trabectedin—Oedema peripheral—Carmustine—lymphatic system cancer	0.000166	0.00278	CcSEcCtD
Trabectedin—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000166	0.00278	CcSEcCtD
Trabectedin—Dyspepsia—Fludarabine—lymphatic system cancer	0.000165	0.00276	CcSEcCtD
Trabectedin—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.000163	0.00273	CcSEcCtD
Trabectedin—Decreased appetite—Fludarabine—lymphatic system cancer	0.000163	0.00273	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000161	0.00271	CcSEcCtD
Trabectedin—Fatigue—Fludarabine—lymphatic system cancer	0.000161	0.0027	CcSEcCtD
Trabectedin—Constipation—Fludarabine—lymphatic system cancer	0.00016	0.00268	CcSEcCtD
Trabectedin—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000158	0.00265	CcSEcCtD
Trabectedin—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000157	0.00264	CcSEcCtD
Trabectedin—Hypersensitivity—Teniposide—lymphatic system cancer	0.000157	0.00263	CcSEcCtD
Trabectedin—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000157	0.00263	CcSEcCtD
Trabectedin—Flushing—Carmustine—lymphatic system cancer	0.000156	0.00262	CcSEcCtD
Trabectedin—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.000155	0.00261	CcSEcCtD
Trabectedin—Anaemia—Bleomycin—lymphatic system cancer	0.000155	0.0026	CcSEcCtD
Trabectedin—Asthenia—Teniposide—lymphatic system cancer	0.000153	0.00256	CcSEcCtD
Trabectedin—Leukopenia—Bleomycin—lymphatic system cancer	0.00015	0.00252	CcSEcCtD
Trabectedin—Alopecia—Carmustine—lymphatic system cancer	0.000149	0.0025	CcSEcCtD
Trabectedin—Body temperature increased—Fludarabine—lymphatic system cancer	0.000148	0.00248	CcSEcCtD
Trabectedin—Mental disorder—Carmustine—lymphatic system cancer	0.000148	0.00248	CcSEcCtD
Trabectedin—Malnutrition—Carmustine—lymphatic system cancer	0.000147	0.00246	CcSEcCtD
Trabectedin—Cough—Bleomycin—lymphatic system cancer	0.000147	0.00246	CcSEcCtD
Trabectedin—Angiopathy—Vincristine—lymphatic system cancer	0.000146	0.00245	CcSEcCtD
Trabectedin—Diarrhoea—Teniposide—lymphatic system cancer	0.000146	0.00244	CcSEcCtD
Trabectedin—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000145	0.00243	CcSEcCtD
Trabectedin—Myalgia—Bleomycin—lymphatic system cancer	0.000143	0.0024	CcSEcCtD
Trabectedin—Alopecia—Vincristine—lymphatic system cancer	0.000142	0.00238	CcSEcCtD
Trabectedin—Back pain—Carmustine—lymphatic system cancer	0.000142	0.00238	CcSEcCtD
Trabectedin—Mental disorder—Vincristine—lymphatic system cancer	0.000141	0.00236	CcSEcCtD
Trabectedin—Alopecia—Mitoxantrone—lymphatic system cancer	0.000138	0.00232	CcSEcCtD
Trabectedin—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000138	0.00232	CcSEcCtD
Trabectedin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000138	0.00231	CcSEcCtD
Trabectedin—Oedema—Bleomycin—lymphatic system cancer	0.000137	0.0023	CcSEcCtD
Trabectedin—Infection—Bleomycin—lymphatic system cancer	0.000136	0.00228	CcSEcCtD
Trabectedin—Anaemia—Carmustine—lymphatic system cancer	0.000136	0.00227	CcSEcCtD
Trabectedin—Back pain—Vincristine—lymphatic system cancer	0.000135	0.00227	CcSEcCtD
Trabectedin—Vomiting—Teniposide—lymphatic system cancer	0.000135	0.00227	CcSEcCtD
Trabectedin—Sepsis—Methotrexate—lymphatic system cancer	0.000135	0.00226	CcSEcCtD
Trabectedin—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000134	0.00225	CcSEcCtD
Trabectedin—Asthenia—Fludarabine—lymphatic system cancer	0.000134	0.00225	CcSEcCtD
Trabectedin—Rash—Teniposide—lymphatic system cancer	0.000134	0.00225	CcSEcCtD
Trabectedin—Dermatitis—Teniposide—lymphatic system cancer	0.000134	0.00225	CcSEcCtD
Trabectedin—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000133	0.00224	CcSEcCtD
Trabectedin—Headache—Teniposide—lymphatic system cancer	0.000133	0.00224	CcSEcCtD
Trabectedin—Back pain—Mitoxantrone—lymphatic system cancer	0.000132	0.00221	CcSEcCtD
Trabectedin—Leukopenia—Carmustine—lymphatic system cancer	0.000131	0.0022	CcSEcCtD
Trabectedin—Anorexia—Bleomycin—lymphatic system cancer	0.000131	0.00219	CcSEcCtD
Trabectedin—Anaemia—Vincristine—lymphatic system cancer	0.000129	0.00217	CcSEcCtD
Trabectedin—Hypotension—Bleomycin—lymphatic system cancer	0.000128	0.00215	CcSEcCtD
Trabectedin—Diarrhoea—Fludarabine—lymphatic system cancer	0.000128	0.00215	CcSEcCtD
Trabectedin—Nausea—Teniposide—lymphatic system cancer	0.000126	0.00212	CcSEcCtD
Trabectedin—Anaemia—Mitoxantrone—lymphatic system cancer	0.000126	0.00211	CcSEcCtD
Trabectedin—Hepatic failure—Methotrexate—lymphatic system cancer	0.000125	0.0021	CcSEcCtD
Trabectedin—Leukopenia—Vincristine—lymphatic system cancer	0.000125	0.0021	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000125	0.00209	CcSEcCtD
Trabectedin—Myalgia—Carmustine—lymphatic system cancer	0.000125	0.00209	CcSEcCtD
Trabectedin—Paraesthesia—Bleomycin—lymphatic system cancer	0.000123	0.00206	CcSEcCtD
Trabectedin—Dyspnoea—Bleomycin—lymphatic system cancer	0.000122	0.00205	CcSEcCtD
Trabectedin—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000122	0.00205	CcSEcCtD
Trabectedin—Oedema—Carmustine—lymphatic system cancer	0.00012	0.00201	CcSEcCtD
Trabectedin—Decreased appetite—Bleomycin—lymphatic system cancer	0.000119	0.002	CcSEcCtD
Trabectedin—Myalgia—Vincristine—lymphatic system cancer	0.000119	0.002	CcSEcCtD
Trabectedin—Cough—Mitoxantrone—lymphatic system cancer	0.000119	0.002	CcSEcCtD
Trabectedin—Infection—Carmustine—lymphatic system cancer	0.000119	0.00199	CcSEcCtD
Trabectedin—Vomiting—Fludarabine—lymphatic system cancer	0.000119	0.00199	CcSEcCtD
Trabectedin—Rash—Fludarabine—lymphatic system cancer	0.000118	0.00198	CcSEcCtD
Trabectedin—Dermatitis—Fludarabine—lymphatic system cancer	0.000118	0.00198	CcSEcCtD
Trabectedin—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000117	0.00197	CcSEcCtD
Trabectedin—Headache—Fludarabine—lymphatic system cancer	0.000117	0.00196	CcSEcCtD
Trabectedin—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000116	0.00195	CcSEcCtD
Trabectedin—Myalgia—Mitoxantrone—lymphatic system cancer	0.000116	0.00195	CcSEcCtD
Trabectedin—Oedema—Vincristine—lymphatic system cancer	0.000114	0.00192	CcSEcCtD
Trabectedin—Anorexia—Carmustine—lymphatic system cancer	0.000114	0.00191	CcSEcCtD
Trabectedin—Infection—Vincristine—lymphatic system cancer	0.000113	0.0019	CcSEcCtD
Trabectedin—Nervous system disorder—Vincristine—lymphatic system cancer	0.000112	0.00188	CcSEcCtD
Trabectedin—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000112	0.00188	CcSEcCtD
Trabectedin—Hypotension—Carmustine—lymphatic system cancer	0.000112	0.00188	CcSEcCtD
Trabectedin—Oedema—Mitoxantrone—lymphatic system cancer	0.000111	0.00187	CcSEcCtD
Trabectedin—Nausea—Fludarabine—lymphatic system cancer	0.000111	0.00186	CcSEcCtD
Trabectedin—Infection—Mitoxantrone—lymphatic system cancer	0.000111	0.00185	CcSEcCtD
Trabectedin—Shock—Mitoxantrone—lymphatic system cancer	0.000109	0.00184	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000109	0.00183	CcSEcCtD
Trabectedin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000109	0.00183	CcSEcCtD
Trabectedin—Anorexia—Vincristine—lymphatic system cancer	0.000109	0.00183	CcSEcCtD
Trabectedin—Body temperature increased—Bleomycin—lymphatic system cancer	0.000108	0.00182	CcSEcCtD
Trabectedin—Insomnia—Carmustine—lymphatic system cancer	0.000108	0.00182	CcSEcCtD
Trabectedin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000108	0.00181	CcSEcCtD
Trabectedin—Paraesthesia—Carmustine—lymphatic system cancer	0.000107	0.0018	CcSEcCtD
Trabectedin—Hypotension—Vincristine—lymphatic system cancer	0.000107	0.00179	CcSEcCtD
Trabectedin—Dyspnoea—Carmustine—lymphatic system cancer	0.000107	0.00179	CcSEcCtD
Trabectedin—Anorexia—Mitoxantrone—lymphatic system cancer	0.000106	0.00178	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000104	0.00175	CcSEcCtD
Trabectedin—Decreased appetite—Carmustine—lymphatic system cancer	0.000104	0.00174	CcSEcCtD
Trabectedin—Hypotension—Mitoxantrone—lymphatic system cancer	0.000104	0.00174	CcSEcCtD
Trabectedin—Insomnia—Vincristine—lymphatic system cancer	0.000103	0.00173	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000103	0.00173	CcSEcCtD
Trabectedin—Paraesthesia—Vincristine—lymphatic system cancer	0.000103	0.00172	CcSEcCtD
Trabectedin—Constipation—Carmustine—lymphatic system cancer	0.000102	0.00172	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000101	0.0017	CcSEcCtD
Trabectedin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000101	0.00169	CcSEcCtD
Trabectedin—Paraesthesia—Mitoxantrone—lymphatic system cancer	9.99e-05	0.00168	CcSEcCtD
Trabectedin—Decreased appetite—Vincristine—lymphatic system cancer	9.93e-05	0.00167	CcSEcCtD
Trabectedin—Dyspnoea—Mitoxantrone—lymphatic system cancer	9.92e-05	0.00166	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	9.86e-05	0.00165	CcSEcCtD
Trabectedin—Fatigue—Vincristine—lymphatic system cancer	9.85e-05	0.00165	CcSEcCtD
Trabectedin—Asthenia—Bleomycin—lymphatic system cancer	9.84e-05	0.00165	CcSEcCtD
Trabectedin—Dyspepsia—Mitoxantrone—lymphatic system cancer	9.79e-05	0.00164	CcSEcCtD
Trabectedin—Gastrointestinal pain—Carmustine—lymphatic system cancer	9.79e-05	0.00164	CcSEcCtD
Trabectedin—Constipation—Vincristine—lymphatic system cancer	9.77e-05	0.00164	CcSEcCtD
Trabectedin—Decreased appetite—Mitoxantrone—lymphatic system cancer	9.67e-05	0.00162	CcSEcCtD
Trabectedin—Fatigue—Mitoxantrone—lymphatic system cancer	9.59e-05	0.00161	CcSEcCtD
Trabectedin—Constipation—Mitoxantrone—lymphatic system cancer	9.51e-05	0.0016	CcSEcCtD
Trabectedin—Body temperature increased—Carmustine—lymphatic system cancer	9.46e-05	0.00159	CcSEcCtD
Trabectedin—Abdominal pain—Carmustine—lymphatic system cancer	9.46e-05	0.00159	CcSEcCtD
Trabectedin—Gastrointestinal pain—Vincristine—lymphatic system cancer	9.34e-05	0.00157	CcSEcCtD
Trabectedin—Pancytopenia—Methotrexate—lymphatic system cancer	9.26e-05	0.00155	CcSEcCtD
Trabectedin—Neutropenia—Methotrexate—lymphatic system cancer	9.11e-05	0.00153	CcSEcCtD
Trabectedin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	9.1e-05	0.00153	CcSEcCtD
Trabectedin—Body temperature increased—Vincristine—lymphatic system cancer	9.03e-05	0.00151	CcSEcCtD
Trabectedin—Abdominal pain—Vincristine—lymphatic system cancer	9.03e-05	0.00151	CcSEcCtD
Trabectedin—Hypersensitivity—Carmustine—lymphatic system cancer	8.82e-05	0.00148	CcSEcCtD
Trabectedin—Abdominal pain—Mitoxantrone—lymphatic system cancer	8.79e-05	0.00148	CcSEcCtD
Trabectedin—Body temperature increased—Mitoxantrone—lymphatic system cancer	8.79e-05	0.00148	CcSEcCtD
Trabectedin—Vomiting—Bleomycin—lymphatic system cancer	8.72e-05	0.00146	CcSEcCtD
Trabectedin—Infestation NOS—Methotrexate—lymphatic system cancer	8.69e-05	0.00146	CcSEcCtD
Trabectedin—Infestation—Methotrexate—lymphatic system cancer	8.69e-05	0.00146	CcSEcCtD
Trabectedin—Rash—Bleomycin—lymphatic system cancer	8.64e-05	0.00145	CcSEcCtD
Trabectedin—Dermatitis—Bleomycin—lymphatic system cancer	8.64e-05	0.00145	CcSEcCtD
Trabectedin—Asthenia—Carmustine—lymphatic system cancer	8.59e-05	0.00144	CcSEcCtD
Trabectedin—Stomatitis—Methotrexate—lymphatic system cancer	8.47e-05	0.00142	CcSEcCtD
Trabectedin—Hypersensitivity—Vincristine—lymphatic system cancer	8.42e-05	0.00141	CcSEcCtD
Trabectedin—Hepatobiliary disease—Methotrexate—lymphatic system cancer	8.22e-05	0.00138	CcSEcCtD
Trabectedin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	8.2e-05	0.00137	CcSEcCtD
Trabectedin—Asthenia—Vincristine—lymphatic system cancer	8.2e-05	0.00137	CcSEcCtD
Trabectedin—Diarrhoea—Carmustine—lymphatic system cancer	8.19e-05	0.00137	CcSEcCtD
Trabectedin—Nausea—Bleomycin—lymphatic system cancer	8.14e-05	0.00137	CcSEcCtD
Trabectedin—Agranulocytosis—Methotrexate—lymphatic system cancer	8.11e-05	0.00136	CcSEcCtD
Trabectedin—Asthenia—Mitoxantrone—lymphatic system cancer	7.98e-05	0.00134	CcSEcCtD
Trabectedin—Dizziness—Carmustine—lymphatic system cancer	7.91e-05	0.00133	CcSEcCtD
Trabectedin—Haemoglobin—Methotrexate—lymphatic system cancer	7.84e-05	0.00132	CcSEcCtD
Trabectedin—Diarrhoea—Vincristine—lymphatic system cancer	7.82e-05	0.00131	CcSEcCtD
Trabectedin—Haemorrhage—Methotrexate—lymphatic system cancer	7.8e-05	0.00131	CcSEcCtD
Trabectedin—Diarrhoea—Mitoxantrone—lymphatic system cancer	7.61e-05	0.00128	CcSEcCtD
Trabectedin—Vomiting—Carmustine—lymphatic system cancer	7.61e-05	0.00128	CcSEcCtD
Trabectedin—Dizziness—Vincristine—lymphatic system cancer	7.55e-05	0.00127	CcSEcCtD
Trabectedin—Rash—Carmustine—lymphatic system cancer	7.55e-05	0.00127	CcSEcCtD
Trabectedin—Dermatitis—Carmustine—lymphatic system cancer	7.54e-05	0.00126	CcSEcCtD
Trabectedin—Headache—Carmustine—lymphatic system cancer	7.5e-05	0.00126	CcSEcCtD
Trabectedin—Vomiting—Vincristine—lymphatic system cancer	7.26e-05	0.00122	CcSEcCtD
Trabectedin—Rash—Vincristine—lymphatic system cancer	7.2e-05	0.00121	CcSEcCtD
Trabectedin—Dermatitis—Vincristine—lymphatic system cancer	7.2e-05	0.00121	CcSEcCtD
Trabectedin—Headache—Vincristine—lymphatic system cancer	7.16e-05	0.0012	CcSEcCtD
Trabectedin—Nausea—Carmustine—lymphatic system cancer	7.11e-05	0.00119	CcSEcCtD
Trabectedin—Angiopathy—Methotrexate—lymphatic system cancer	7.08e-05	0.00119	CcSEcCtD
Trabectedin—Vomiting—Mitoxantrone—lymphatic system cancer	7.07e-05	0.00119	CcSEcCtD
Trabectedin—Mediastinal disorder—Methotrexate—lymphatic system cancer	7.03e-05	0.00118	CcSEcCtD
Trabectedin—Rash—Mitoxantrone—lymphatic system cancer	7.01e-05	0.00118	CcSEcCtD
Trabectedin—Dermatitis—Mitoxantrone—lymphatic system cancer	7.01e-05	0.00118	CcSEcCtD
Trabectedin—Headache—Mitoxantrone—lymphatic system cancer	6.97e-05	0.00117	CcSEcCtD
Trabectedin—Alopecia—Methotrexate—lymphatic system cancer	6.89e-05	0.00116	CcSEcCtD
Trabectedin—Mental disorder—Methotrexate—lymphatic system cancer	6.84e-05	0.00115	CcSEcCtD
Trabectedin—Malnutrition—Methotrexate—lymphatic system cancer	6.79e-05	0.00114	CcSEcCtD
Trabectedin—Nausea—Vincristine—lymphatic system cancer	6.79e-05	0.00114	CcSEcCtD
Trabectedin—Dysgeusia—Methotrexate—lymphatic system cancer	6.65e-05	0.00112	CcSEcCtD
Trabectedin—Nausea—Mitoxantrone—lymphatic system cancer	6.61e-05	0.00111	CcSEcCtD
Trabectedin—Back pain—Methotrexate—lymphatic system cancer	6.57e-05	0.0011	CcSEcCtD
Trabectedin—Anaemia—Methotrexate—lymphatic system cancer	6.28e-05	0.00105	CcSEcCtD
Trabectedin—Leukopenia—Methotrexate—lymphatic system cancer	6.08e-05	0.00102	CcSEcCtD
Trabectedin—Cough—Methotrexate—lymphatic system cancer	5.93e-05	0.000994	CcSEcCtD
Trabectedin—Myalgia—Methotrexate—lymphatic system cancer	5.78e-05	0.00097	CcSEcCtD
Trabectedin—Arthralgia—Methotrexate—lymphatic system cancer	5.78e-05	0.00097	CcSEcCtD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	5.74e-05	0.000963	CcSEcCtD
Trabectedin—Infection—Methotrexate—lymphatic system cancer	5.51e-05	0.000924	CcSEcCtD
Trabectedin—Nervous system disorder—Methotrexate—lymphatic system cancer	5.44e-05	0.000912	CcSEcCtD
Trabectedin—Thrombocytopenia—Methotrexate—lymphatic system cancer	5.43e-05	0.00091	CcSEcCtD
Trabectedin—Skin disorder—Methotrexate—lymphatic system cancer	5.38e-05	0.000903	CcSEcCtD
Trabectedin—Anorexia—Methotrexate—lymphatic system cancer	5.28e-05	0.000886	CcSEcCtD
Trabectedin—Hypotension—Methotrexate—lymphatic system cancer	5.18e-05	0.000869	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	5.05e-05	0.000847	CcSEcCtD
Trabectedin—Insomnia—Methotrexate—lymphatic system cancer	5.01e-05	0.000841	CcSEcCtD
Trabectedin—Paraesthesia—Methotrexate—lymphatic system cancer	4.98e-05	0.000835	CcSEcCtD
Trabectedin—Dyspnoea—Methotrexate—lymphatic system cancer	4.94e-05	0.000829	CcSEcCtD
Trabectedin—Dyspepsia—Methotrexate—lymphatic system cancer	4.88e-05	0.000818	CcSEcCtD
Trabectedin—Decreased appetite—Methotrexate—lymphatic system cancer	4.82e-05	0.000808	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	4.79e-05	0.000803	CcSEcCtD
Trabectedin—Fatigue—Methotrexate—lymphatic system cancer	4.78e-05	0.000802	CcSEcCtD
Trabectedin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	4.53e-05	0.00076	CcSEcCtD
Trabectedin—Abdominal pain—Methotrexate—lymphatic system cancer	4.38e-05	0.000735	CcSEcCtD
Trabectedin—Body temperature increased—Methotrexate—lymphatic system cancer	4.38e-05	0.000735	CcSEcCtD
Trabectedin—Hypersensitivity—Methotrexate—lymphatic system cancer	4.08e-05	0.000685	CcSEcCtD
Trabectedin—Asthenia—Methotrexate—lymphatic system cancer	3.98e-05	0.000667	CcSEcCtD
Trabectedin—Diarrhoea—Methotrexate—lymphatic system cancer	3.79e-05	0.000636	CcSEcCtD
Trabectedin—Dizziness—Methotrexate—lymphatic system cancer	3.67e-05	0.000615	CcSEcCtD
Trabectedin—Vomiting—Methotrexate—lymphatic system cancer	3.52e-05	0.000591	CcSEcCtD
Trabectedin—Rash—Methotrexate—lymphatic system cancer	3.5e-05	0.000586	CcSEcCtD
Trabectedin—Dermatitis—Methotrexate—lymphatic system cancer	3.49e-05	0.000586	CcSEcCtD
Trabectedin—Headache—Methotrexate—lymphatic system cancer	3.47e-05	0.000582	CcSEcCtD
Trabectedin—Nausea—Methotrexate—lymphatic system cancer	3.29e-05	0.000552	CcSEcCtD
